Parallel Bio's Expansion into Therapeutics, and We're Looking Out for More Potential Cash Flow Challenges -Watertown Bio News RoundUp
Advertisement
705 Mount Auburn offers both built out and shell lab space options along with a best-in-class onsite amenity package.
Thank you to all who attended our life science panel last Tuesday in partnership with the Charles River Regional Chamber. You can watch a recording of the event on WCATV’s website, including insights from a panel discussion of key opinion leaders in Watertown. If you find events like these and our newsletters informative, consider supporting our work.
Parallel Bio Expands Into Therapeutics
After four years of working on their immune system discovery platform, Parallel Bio (headquartered at Cambridge Scientific Labs), announced in an R&D world article last week that they are pivoting to therapeutics development. The company, launched as part of Y Combinator’s summer 2021 class, developed a model “immune system in a dish” as a platform for drug discovery and validation. Their technology uses organoids (small self-organized 3D clusters of cells) derived from a donor patient’s lymph tissue, combined with AI and robotics to assess the potential immune response of drugs across a wide range of different patients, with the goal of providing a more accurate measurement than the animal models currently in use. The company had initially focused on signing partnerships to test other company’s drugs rather than develop their own. One of their initial partnerships, a validation study for a new flu vaccine with Centivax, provided evidence of the vaccine’s ability to trigger an immune response in humans, leading Centivax to advance the vaccine to clinical trials, which started last month.
Buoyed by the success of their commercial partnership, combined with last year’s $21 million Series A raise, and Federal support (both from the FDA and Congress) for organoids as an animal model alternative, Parallel is now starting their own therapeutics development platform. While the company hasn’t yet commented on what diseases they will be targeting, they have been adding both scientist and lab space, according to permits filed with the City. Between bigger companies like Enanta Pharmaceuticals, Kymera Therapeutics and Triveni Bio, midsize firms Seismic Therapeutic and Corner Therapeutics, and newcomers Psithera, LifeMine Therapeutics, and Matchpoint Therapeutics, Parallel is entering a crowded immunology field in Watertown. It will be interesting to see how they navigate this space and decide what therapy they intend to pursue.
With Lyra and Werewolf’s running low on cash, how do the cash runways of Watertown’s other public companies look?
The first two months of 2026 have seen two public companies: Lyra Therapeutics and Werewolf Therapeutics lay off employees and seek a merger or acquisition to preserve their drug programs as they ran low on cash, with Lyra subsequently being delisted from the Nasdaq on 3/17. We decided to check in on Watertown’s other public companies to see how their cash reserves were faring and if there is anyone else facing a cash crunch, with the results collected in the following table:
Note: companies in italics are not headquartered in Watertown, but have a significant laboratory presence in the community.
As shown in the table above, Most public companies in Watertown have a much longer cash runway than Werewolf or Lyra, with most companies reporting enough cash to support operations into late 2027/early 2028. That being said, we will be keeping an eye on Neumora Therapeutics and Acrivon Therapeutics, which have the lowest amounts of cash on hand, haven’t provided an update since November, and have quarterly reports due to be released in the next two weeks. Stay tuned for updates in our March 31 newsletter.
Quick Updates
Arrivals
NeoSplice Inc (Cambridge Scientific Labs) which is focused on identifying new RNA isoforms as therapeutic targets.
That’s it for now, be back in two week with more Watertown biotech news!
